Thermo Fisher Bioproduction Insights

  1. A Clear Path To Rapid, Consistent Biosimilar Development 6/23/2026

    Faster timelines don’t have to come at the expense of quality or consistency. Discover proven strategies to generate stable, high-performing cell lines while reducing risk and supporting reliable scale-up.

  2. Where Speed Meets Complexity In Bioprocess Development 6/18/2026

    Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.

  3. Leveraging Integrated Media Services For Speed And Efficiency 6/12/2026

    Uncertainty in media stability can limit efficiency and scalability in biologics manufacturing. See how a data-driven approach enables more predictable planning and reduces operational strain.

  4. Closing The QC Gap For mAbs: Rapid Answers Without Compromising 6/9/2026

    Monoclonal antibodies are complex biologics requiring precise analytical strategies to monitor critical quality attributes and impurities, with molecular assays like qPCR supporting sensitive detection, product integrity, and regulatory compliance.

  5. Rapid Selection Of High-Performance CHO Basal And Feed Media 5/5/2026

    A CHO-S bispecific antibody program needed a better basal and feed media combination. Learn how the screening of 180 conditions in 12 weeks identified one that delivered 38% higher titers.

  6. Strategic Supply Chain Leadership: Driving Biopharma Growth 4/22/2026

    Amid a volatile pharma supply chain, strategic sourcing is now critical. Prioritizing your raw material supply ensures operational continuity, consistent performance, compliance, and on-time delivery.

  7. Achieving High Cell Purity With The CTS DynaCellect Magnetic Separation System 4/21/2026

    Learn how closed-system automation, combined with expert technical guidance and protocol optimization, turned a persistent manufacturing bottleneck into a reliable, scalable process.

  8. Anticoagulant Selection Influences T Cell Purity And Yield In Whole Blood Isolation 4/21/2026

    Lithium heparin reduces T cell purity to below 50% and spikes CD15+ contamination in whole blood workflows. See which anticoagulants consistently deliver above 90% CD3+ purity.

  9. Scale Up Or Scale Out? Choosing An Adherent Cell Culture Platform 4/21/2026

    Facility space costs up to $1,000/sq ft and planning timelines stretch 18 months, making your adherent cell culture platform choice one of the highest-stakes decisions in vaccine manufacturing scale-up.

  10. How Can Bioprocessing Professionals Evolve Their Manufacturing For Greater Flexibility And Efficiency? 4/21/2026

    Manufacturing flexibility is now a competitive differentiator. Here's how single-use technologies are reshaping bioprocessing facility design, scalability, and sustainability strategy.